<bill session="108" type="h" number="354" updated="2013-07-14T19:00:39-04:00">
  <state datetime="2003-01-27">REFERRED</state>
  <status>
    <introduced datetime="2003-01-27"/>
  </status>
  <introduced datetime="2003-01-27"/>
  <titles>
    <title as="introduced" type="short">North American Prescription Price Equity Act of 2003</title>
    <title as="introduced" type="official">To amend the Internal Revenue Code of 1986 to allow drug manufacturers a credit against income tax if they certify that the price of a drug in the United States market is not greater than its price in the Canadian or Mexican market.</title>
  </titles>
  <sponsor id="400116"/>
  <cosponsors/>
  <actions>
    <action state="REFERRED" datetime="2003-01-27">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Taxation"/>
    <term name="Canada"/>
    <term name="Commerce"/>
    <term name="Drug industry"/>
    <term name="Health"/>
    <term name="Income tax"/>
    <term name="Latin America"/>
    <term name="Mexico"/>
    <term name="Prescription pricing"/>
    <term name="Tax credits"/>
    <term name="Tax deductions"/>
    <term name="Wholesale trade"/>
  </subjects>
  <amendments/>
  <summary>1/27/2003--Introduced.
North American Prescription Price Equity Act of 2003 - Amends the Internal Revenue Code to allow drug manufacturers a limited tax credit if they certify that the wholesale price of a drug in the United States market is not greater than its wholesale price in the Canadian or Mexican market.</summary>
</bill>
